Sunovion (United Kingdom)
On July 1, 2023, Sunovion Pharmaceuticals Inc. became part of Sumitomo Pharma America, Inc., a biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Sunovion (United Kingdom), United Kingdom, covering academic research published from 2002 to 2023. Read More.
Open Access Percentage
55%
Total
Publications
107
Total Open
Publications
59
Total
Citations
880
Open Access
Percentage
55%
Total
Publications
107
Total Open
Publications
59
Total
Citations
880
Breakdown
Publisher Open
23%
Both
23%
Other Platform Open
9%
Closed
45%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 8%
4
Hybrid 32%
16
No Guarantees 60%
30
Other Platform Open
Domain 79%
27
Other Internet 15%
5
Public 12%
4
Institution 9%
3
Preprint 3%
1
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 27 |
Europe PMC | Domain | 12 |
Unknown Repository | Other Internet | 4 |
Semantic Scholar | Public | 4 |
University of Leeds, The University of Sheffield, University of York - White Rose Research Online | Institution | 2 |
The University of Kansas - KU ScholarWorks | Institution | 1 |
spiral.imperial.ac.uk | Institution | 1 |
Research Square | Preprint | 1 |
Queen Mary University of London - Queen Mary Research Online | Institution | 1 |
DiVA.org | Other Internet | 1 |